Doçent Doktor Orhan Şencan

• Kanser tanısı almış hastaların değerlendirilmesi, ileri tanı ve tedavi planlaması
• Meme
• Akciğer
• Yemek borusu
• Mide
• Karaciğer
• Pankreas
• Bağırsaklar
• Rektum
• Prostat
• Mesane
• Böbrek
• Yumurtalık
• Rahım ve diğer organların kanserleri

• Kemoterapi,
• İmmünoterapi,
• Akıllı İlaç Tedavisi (Hedefe Yönelik Tedaviler)
• Hormonal tedavi gibi çeşitli kanser tedavi yöntemlerinin uygulanması

• Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results–a Turkish Oncology Group Trial. Oncology.85(6):328-35, 2013
• Demirkazik A, Asik M, Yalcin B, Dogan M, Buyukcelik A, Sencan O, Utkan G, Akbulut H, Icli F. The prognostic importance of Leucocytosis, thrombocytosis and serum cascular endothelial growth factor (VEGF) level in inoperable non-small cell lung cancer (NSCLC): A match-pair analysis. International Journal of Hematology and Oncology; 20:14-19, 2010
• Yaman E, Yalçın B, Utkan G, Akbulut H, Işıkdoğan A, Şencan O, Büyükçelik A, Pamir A, Demirkazık A, İçli F. Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with Sarcomas. International Journal of Hematology and Oncology; 18:79-84, 2008
• Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. European Journal of Cancer Care 2008, 17, 26–32
• Boruban C, Sencan O, Akmansu M, Atik ET, Ozbek S. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
Anticancer Drugs. 2007 Sep;18(8):969-72.
• Dogan M, Demirkazik A, Konuk N, Yalcin B, Buyukcelik A, Utkan G, Tek I, Akbulut H, Sencan O, Icli F.The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study. Int J Biol Markers. 2006 Oct-Dec;21(4):206-10.
• Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• Boruban C, Yavas O, Altundag K, Sencan O. Synchronous presentation of nasopharyngeal and renal cell carcinomas. Int Braz J Urol. 2006 May-Jun;32(3):310-2.
• Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):197-200.
• Icli F, Akbulut H, Uner A, Yalcin B, Baltalı E, Altinbas M, Coskun Ş, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, SakSD. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer, 92:639–644, 2005
• Yalcin B, Akbulut H, Buyukcelik A, Sencan O, Demirkazik A, Onur H, Senler FC, Dincol D, Icli F. The Effects of Chronomodulated Therapy with 5-Fluorouracil (5-Fu) and Folinic Acid (Fa) on the Toxicity and Quality of Life in Patients with Advanced Gastric Cancer. Biological Rhythm Research, 35 (4/5):259–268, 2004
• Dincol D, Samur M, Pamir A, Sencan O, Akbulut H, Yalçın B, Onur H, Demirkazık A, Şenler FÇ, Içli F. Prospective Randomized Comparison of the a.m. versus p.m. Daily Single Subcutaneous Administration of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). Cancer, 88:2033-6, 2000
• Arıcan A, İçli F, Akbulut H, Çakır M, Şencan O, Samur M, Açıkgöz N, Demirkazık A. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Medical Oncology, 16:204-210, 1999,

• Yalcin S, Uslu S, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study. (Poster) 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 01-06, 2012, Chicago, IL, USA. Journal of Clinical Oncology, 30(15): A3565, 20112
• Yalcin B, Gunaydin Y, Percinel S, Dogan M, Urun Y, Ozal FG, Utkan G, Akbulut H, Icli F, Sencan O. Status of Granulocyte Colony-Stimulating Factor Receptor in Tumour Tissue of Patients With Breast Cancer . (Poster) European Multidisciplinary Cancer Congress (ESMO 36, ECCO 16), September 23-27, 2011, Stocholm, Sweden, European Journal of Cancer, Volume 47, Supplement 1, September 2011, Pages: S361-S361
• Urun Y, Yalcin B, Karatas F, Utkan G, Yuksel C, Cangir AK, Senler FC, Demirkazik A, Akbulut H, Icli F, Sencan O. The Significance of the Serum Leptin, Ghreline, Tumour Necrosis Factor Alpha and Interleukine-1 Levels in Patients With Non-Small Cell Lung Cancer. (Poster), European Multidisciplinary Cancer Congress (ESMO 36, ECCO 16), September 23-27, 2011, Stocholm, Sweden, European Journal of Cancer, Volume 47, Supplement 1, September 2011, Pages S612
• S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber, C. Camci, O. Sencan and S. Kilickap. A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer. (Poster) ASCO 2011 Gastrointestinal Cancer Symposium, January 20-22, 2011, San Francisco, CA, USA
• Doğan M, Şencan O, Yalçın B, Büyükçelik A, Utkan G, Çay Şenler F, Onur H, Akbulut H, Demirkazık A, Dinçol D, İçli F. Retrospective analysis of 18 cancer patients with secondary primary gastrointestinal cancers. (Poster) 18th Intrnational Postgraduate Course of the International Association of Surgeons, Gastroenterologists and Oncologists, October, 2008.
• Doğan M, Şencan O, Yalçın B, Utkan G, Büyükçelik A, Onur H, Çay Şenler F, Akbulut H, Demirkazık A, Dinçol D, İçli F. Second primary cancers in 11 patients with gastrointestinal malignancies. (Poster) 18th International Postgraduate Course of the International Association of Surgeons, Gastroenterologists and Oncologists, October, 2008.
• Dogan M, Utkan G, Buyukcelik A, Yalcin B, Sencan O, Icli F. Single center experience in 101 non-Hodgkin lymphoma patients. Published in Proceedings book of the 7th Congress of BUON (Balkan Union of Oncology), October 16-19, 2008, İzmir, Turkiye
• Dogan M, Utkan G, Sencan O, Yalcin B, Buyukcelik A, Onur H, Cay Senler F, Demirkazik A, Dincol D, Icli F. Multiple primary tumors in 49 cases. (Poster) 33rd ESMO Congress, September 12-16, 2008, Stocholm, Sweden
• Utkan G, Dogan M, Yalcin B, Sencan O, Karakilic E, Buyukcelik A, Ozal G, Cay Senler F, Demirkazik A, Icli F. Sixteen patients with malignant mesothelioma at one center. Published in Abstract Book of the 33rd ESMO Congress, September 12-16, 2008, Stocholm, Sweden
• Boruban C, Babaoglu MO, Sencan O, Bozkurt A, Yasar U. Tamoxifen inhibits cytochrome P450 2C9 activity: A possible mechanism for tamoxifen-warfarin interaction.. J Clin Oncol (ASCO Meeting Abstracts) 22(14S): 2133, 2004
• Sencan O, Demirkazik A, Akbulut H, Yalcin B, İcli F. Comparison of 5-fluorouracil-folinic acid and etoposide-doxorubicin-cisplatin chemotherapies in patients with advanced gastric carcinoma: A prospective randomized crossover study, interim analysis. Published in Abstract Book of the 25th ESMO Congress, October 13-17, 2000, Hamburg, Germany
• Akbulut H, İçli F, Yalçın B, Şencan O, Büyükçelik A, Dinçol D, Demirkazık A, Onur H, Çay Şenler F. The efficacy of irinotecan in patients with colorectal carcinoma resistant to 5-FU. (Poster) EORTC-FFCD Joint Meeting: Liver and Gastro-Intestinal Tract Cancers, 23 – 26 June 1999, Paris, France
• Arican A, Dinçol D, Samur M, Demirkazik A, Şencan O, Akbulut H, Karaoguz H, Çay F, İçli F. Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer (Poster) The First European Conference on the Economics of Cancer, 19-21 November 1997, Brussels, Belgium

• ESMO (European Society for Medical Oncology) Congress 2019, Sep 27 – Oct 1, 2019, Barcelona, Spain
• The American Society of Clinical Oncology 2013 Annual Meeting, May 31 – June 4, 2013, Chicago, Illinois, USA
• The American Society of Clinical Oncology 2012 Annual Meeting, June 1 – 5, 2012, Chicago, Illinois, USA
• The American Society of Clinical Oncology 2008 Annual Meeting, May 28 – June 6, 2008, Chicago, Illinois, USA
• 10th International Conference, Primary Therapy of Early Breast Cancer, March 14 – 17, 2007, St. Gallen, Switzerland
• ESMO (European Society for Medical Oncology) Course on Palliative Care in Oncology, November 17 – 18, 2006, Ankara
• 31st ESMO (European Society for Medical Oncology) Congress, September 29 – October 3, 2006, Istanbul, Turkiye
• 8th World Congress on Gastrointestinal Cancer, June 28 – July 1, 2006, Barcelona, Spain
• The American Society of Clinical Oncology 2006 Annual Meeting,
June 2 – 6, 2006, Atlanta, Georgia, USA
• ECCO 13, the European Cancer Conference, October 30 – December 3, 2005, Paris, France
• ESMO (European Society for Medical Oncology) Course, How to Practice Evidence Based Medicine, July 22 – 24, 2004, Antwerp, Belgium
• The American Society of Clinical Oncology 2004 Annual Meeting, June 5 – 8, 2004, New Orleans, Louisiana, USA
• 3rd International Forum on Oncology and Health Economics (organized by CECOG – Central European Cooperative Oncology Group), October 11 – 12, 2003, Vienna, Austria
• ECCO 12, the European Cancer Conference, September 21 – 25, 2003, Copenhagen, Denmark
• ESMO (European Society for Medical Oncology) Summer Educational Conference, June 19 – 22, 2003, Edinburgh, Scotland, UK
• 8th International Conference, Primary Therapy of Early Breast Cancer, March 12 – 15, 2003, St. Gallen, Switzerland
• 25th San Antonio Breast Cancer Symposium, December 11 – 14, 2002, San Antonio, Texas, U.S.A.
• 4th International Conference Perspectives in Colorectal Cancer, a Consensus Meeting, June 20 – 22, 2002, Barcelona, Spain
• The American Society of Clinical Oncology 2002 Annual Meeting, May 18 – 21, 2002, Orlando, Florida, USA
• 25th ESMO (European Society for Medical Oncology) Congress, October 13 – 17, 2000, Hamburg, Germany ESMO Postgraduate Course: Basic Course in Medical Oncology, April 12-16, 2000, Antalya, Turkiye
• ESMO (European Society for Medical Oncology) Postgraduate Course: Basic Course in Medical Oncology, April 12-16, 2000, Antalya, Turkiye
• 10th International Congress on Anti-Cancer Treatment, January 31 – February 3, 2000, Paris, France
• 23rd ESMO (European Society for Medical Oncology) Congress, 6-10 November 1998, Athens, Greece

• Amerikan Klinik Onkoloji Derneği (ASCO)
• Avrupa Tıbbi Onkoloji Derneği (ESMO)
• Türk Tıbbi Onkoloji Derneği
• Türk Onkoloji Grubu (TOG)
• Türk İç Hastalıkları Uzmanlık Derneği (2002-2004 yılları arasında Yönetim Kurulu Üyesi)
• İstanbul Tabip Odası, Türkiye